These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 28670972)

  • 1. Testing for qualitative heterogeneity: An application to composite endpoints in survival analysis.
    Oulhaj A; El Ghouch A; Holman RR
    Stat Methods Med Res; 2019 Jan; 28(1):151-169. PubMed ID: 28670972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introducing a new estimator and test for the weighted all-cause hazard ratio.
    Ozga AK; Rauch G
    BMC Med Res Methodol; 2019 Jun; 19(1):118. PubMed ID: 31185922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial.
    Xiong C; Yu K; Gao F; Yan Y; Zhang Z
    Clin Trials; 2005; 2(5):387-93. PubMed ID: 16317808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
    Eaton A; Therneau T; Le-Rademacher J
    Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Monte Carlo approach for change-point detection in the Cox proportional hazards model.
    Liu M; Lu W; Shao Y
    Stat Med; 2008 Aug; 27(19):3894-909. PubMed ID: 18254131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sizing clinical trials when comparing bivariate time-to-event outcomes.
    Sugimoto T; Hamasaki T; Evans SR; Sozu T
    Stat Med; 2017 Apr; 36(9):1363-1382. PubMed ID: 28120524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of Cox regression models for composite time-to-event endpoints with component-wise censoring in randomized trials.
    Speiser JL; Ambrosius WT; Pajewski NM
    Clin Trials; 2023 Oct; 20(5):507-516. PubMed ID: 37243355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic comparison of recurrent event models for application to composite endpoints.
    Ozga AK; Kieser M; Rauch G
    BMC Med Res Methodol; 2018 Jan; 18(1):2. PubMed ID: 29301487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Easily applicable multiple testing procedures to improve the interpretation of clinical trials with composite endpoints.
    Schüler S; Mucha A; Doherty P; Kieser M; Rauch G
    Int J Cardiol; 2014 Jul; 175(1):126-32. PubMed ID: 24861257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of statistical issues with progression-free survival as an interval-censored time-to-event endpoint.
    Sun X; Li X; Chen C; Song Y
    J Biopharm Stat; 2013; 23(5):986-1003. PubMed ID: 23957511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous inference of a binary composite endpoint and its components.
    Große Ruse M; Ritz C; Hothorn LA
    J Biopharm Stat; 2017; 27(1):56-69. PubMed ID: 26881805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials.
    Bakal JA; Westerhout CM; Armstrong PW
    Stat Methods Med Res; 2015 Dec; 24(6):980-8. PubMed ID: 22275378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential parallel comparison design with two coprimary endpoints.
    Homma G; Daimon T
    Pharm Stat; 2020 May; 19(3):243-254. PubMed ID: 31829521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new approach for sizing trials with composite binary endpoints using anticipated marginal values and accounting for the correlation between components.
    Bofill Roig M; Gómez Melis G
    Stat Med; 2019 May; 38(11):1935-1956. PubMed ID: 30637797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods for the analysis of multiple endpoints in small populations: A review.
    Ristl R; Urach S; Rosenkranz G; Posch M
    J Biopharm Stat; 2019; 29(1):1-29. PubMed ID: 29985752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On weighted composite scores for early Alzheimer's trials.
    Jin K; Cameron B; Dunn B
    Pharm Stat; 2019 Mar; 18(2):239-247. PubMed ID: 30565432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size determination and re-estimation for matched pair designs with multiple binary endpoints.
    Xu J; Yu M
    Biom J; 2013 May; 55(3):430-43. PubMed ID: 23553605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials.
    Claggett B; Pocock S; Wei LJ; Pfeffer MA; McMurray JJV; Solomon SD
    Circulation; 2018 Aug; 138(6):570-577. PubMed ID: 29588314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Misspecification of Cox regression models with composite endpoints.
    Wu L; Cook RJ
    Stat Med; 2012 Dec; 31(28):3545-62. PubMed ID: 22736519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hazard ratio inference in stratified clinical trials with time-to-event endpoints and limited sample size.
    Xu R; Mehrotra DV; Shaw PA
    Pharm Stat; 2019 May; 18(3):366-376. PubMed ID: 30706642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.